A 28-year-old man is evaluated in the outpatient psychiatry clinic during a routine follow… — USMLE Step 3

A $28$ -year-old man is evaluated in the outpatient psychiatry clinic during a routine follow-up. He has a history of treatment-resistant schizophrenia and was started on clozapine $4$ weeks ago. The patient reports a significant reduction in auditory hallucinations and feels that his mood has stabilized. He currently has no somatic complaints, including no fever, sore throat, cough, or dysuria. His vital signs are temperature $37.0^\circ\text{C}$ ( $98.6^\circ\text{F}$ ), blood pressure $118/76\text{ mmHg}$ , heart rate $82/\text{min}$ , and respiratory rate $14/\text{min}$ . Physical examination is unremarkable.

A complete blood count drawn today reveals:
White blood cell count: $4,500/\text{mm}^3$
Absolute neutrophil count: $1,200/\text{mm}^3$

His baseline absolute neutrophil count prior to initiating therapy was $3,800/\text{mm}^3$ . Which of the following is the most appropriate next step in the management of this patient?

Continue clozapine and increase the frequency of absolute neutrophil count monitoring to three times weeklyAnswer
B
Discontinue clozapine immediately and transition to a different atypical antipsychotic
C
Suspend clozapine and admit the patient to the hospital for reverse isolation and prophylactic antibiotics
D
Perform a bone marrow aspiration and biopsy to evaluate for evolving aplastic anemia
E
Add carbamazepine to the current regimen to augment the antipsychotic effect and stimulate leukocytosis

Answer

Continue clozapine and increase the frequency of absolute neutrophil count monitoring to three times weekly.

The correct action is to continue the medication and increase monitoring frequency. Clozapine is highly effective for treatment-resistant schizophrenia but carries a known risk of severe neutropenia and agranulocytosis. The Clozapine Risk Evaluation and Mitigation Strategy (REMS) guidelines mandate strict monitoring protocols. In the general population, an absolute neutrophil count (ANC) between

1,000/\text{mm}^3

and

1,499/\text{mm}^3

constitutes mild neutropenia. Because this patient is asymptomatic and lacks signs of infection, the standard of care is to maintain the current clozapine dose and increase ANC monitoring to three times weekly. Therapy is only interrupted if the ANC falls below

1,000/\text{mm}^3

or if the patient develops signs of a systemic infection.

Step-by-Step Solution

Calculate or identify the severity of the patient's neutropenia based on the provided laboratory results.

The patient has an absolute neutrophil count (ANC) of 1,200/mm³, which falls into the category of mild neutropenia (1,000 to 1,499/mm³).

Correct application of the clozapine Risk Evaluation and Mitigation Strategy (REMS) protocol requires precise categorization of the ANC.

Correlate the laboratory finding with the patient's clinical presentation.

The patient is completely asymptomatic with normal vital signs, ruling out an acute infectious process.

The presence of fever or infection would necessitate immediate cessation of therapy regardless of the specific neutropenia tier.

Determine the algorithmic next step according to established safety guidelines.

For mild neutropenia in the general population, clozapine should be continued, and ANC monitoring should be increased to three times weekly until the ANC is ≥ 1,500/mm³.

This balances the critical need to maintain psychiatric stability in treatment-resistant schizophrenia against the risk of progression to severe agranulocytosis.

Key Concept

Monitoring clozapine-induced neutropenia and applying REMS guidelines

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic